Method for increasing productivity in cattle

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with applying selector as a selenium-containing organic preparation to be introduced for cows and calves monthly intramuscularly at the dosage of 10 mcg/kg body weight. The method provides decreased fodder expenses for the synthesis of the production obtained.

EFFECT: higher productivity in cattle.

2 ex, 7 tbl

 

The invention relates to the field of agriculture, and in particular to methods of increasing the productivity of cattle.

Cattle breeding is one of the leading sectors of livestock, which produces almost all the milk and the bulk of meat. Stabilization and development of dairy and beef cattle is largely determined by selection and breeding work, but primarily by the level and usefulness of feeding, the rational use of biologically active food components, trace elements, vitamins, enzymes, antioxidants and other substances that contribute to increasing the productive action of the feed ration.

It is known the use of sodium Selenite to increase the productivity of cattle /1/.

The disadvantages of this method are the high toxicity and low efficiency.

A known way of increasing the productivity and nonspecific resistance of calves, providing injecting calves aged 2 and 4 months subcutaneously or intramuscularly prolonged form of organic selenium compounds in the form of selenopyran at the rate of 100 mg per head in each of the two injection /2/.

The disadvantages of this method include the need for the use as solvent of the drug only fat, which increases the cost of the awn processing. In addition, the resistance of calves mainly reduced in the first 3 weeks after birth and the use of selenopyran at the age of 2 - and 4-months not already renders prophylactic action of the gastro-intestinal tract and respiratory organs, i.e. gastroenteritis and pneumonia. The disadvantages of this method include the complexity of the technology of preparation of the drug.

The prototype of the invention is a method of increasing milk production and nonspecific resistance of newly calved cows, introducing a dry cows 15 days before calving once prolonged parenteral forms of selenopyran containing 300 mg of selenopyran /3/.

The disadvantages of the prototype are:

- the use of expensive fat for the preparation of injectable form of the drug,

- high dose of 300 mg;

low therapeutic range;

- a short shelf life - 1 year;

- loss of use of animal products after applying selenopyran within 10 days.

The technical result of the invention is the improvement of cattle productivity and improving the quality of milk and meat from him.

The method is as follows.

Cows and calves injected intramuscularly monthly selecor at a dose of 10 mg/kg of body weight.

Selecor (dimethylpyrazole elemid) - the drug is an antioxidant containing an organic form of selenium /4/.

Can reasonably be argued that the selenium products have potent antioxidant and are a new generation of highly efficient regulators of vital processes of a living organism and treatment tools.

The use of selecor lactating cows increases average daily milk yield, the yield of milk fat, reduces the cost of feed for milk production; in calves receiving selecor during rearing, increased average daily gain, and feed costs are reduced.

In the available literature found no data about the use of selecor to increase the productivity of cattle that demonstrates compliance with the proposed method the criterion of "novelty".

Research-and-economic experiments are conducted on the basis of CJSC PTF "Zadonsk" Zadonsky district, Lipetsk region, the Department of the feeding of the Voronezh state agrarian University, Department of physical-chemical studies of the all-Russian research veterinary Institute of pathology, pharmacology and therapy, Zadonsky district and Lipetsk regional veterinary laboratories.

The essence of the method is illustrated by examples

Example 1.

Milk yield of cows and milk quality at approx the securing of sodium Selenite and selecor.

Scientific and business experience in the study of milk production and milk quality using the claimed and known methods conducted on 30 cows - analogues for the yield of milk, age, breed, lactation, time of calving, distributed into three groups: a control and two experimental. Cows experimental groups were injected intramuscularly monthly: 0.5%aqueous solution of sodium Selenite at a dose of 10 ml per animal (experimental group 1); 1,5%water-alcohol solution selecor dose (LW) 10 g/kg body weight (experimental group 2). Cows in the control group of drugs were introduced.

Animals of the control and experimental groups were housed under identical conditions care and maintenance and used General ration, consisting of 5 kg of barley straw, 20 kg of silage corn, 0.5 kg of molasses, 1 kg of barley, 1 kg of sunflower meal, 10 kg of sugar beet pulp total nutritional value 10,46 fodder units and 869 g of digestible protein.

Milk production of cows was considered by conducting monthly monitoring of milkings during two consecutive days. Milk production by month established by multiplying its control milking on days of the month. Milk samples were investigated on a monthly basis. For this purpose it was collected daily samples for adjacent day in proportion to the yield of milk. As preservative used the hydrogen peroxide.

Observation of animals were conducted within three months.

The efficacy of the drugs was assessed by milk production, milk quality (density, acidity, protein, SNF, lactose, calcium, phosphorus, fat, size and number of fat globules), expected feed consumption per kg of produced milk and its energy value.

The results are shown in tables 1,2.

Table 1
Milk yield of cows in connection with the use of sodium Selenite and selecor.
IndicatorsGroup
controlExperienced 1experienced 2
Gross milk production per cow for 90 days, kg893919955
The fat content of milk, %3,65±0,073,64±0,103,69±0,15
Made of milk fat, kg32,533,535,2
%100,0103,1108,3
Gain milk in recalculation on the basis (3,8%) fat (kg)858880927
%100,0102,6108,0

Table 2.
The composition and properties of milk cows in the control and experimental groups.
IndicatorsGroup
controlexperienced 1experienced 2
Dry matter, %11,95±0,0912,08±0,0812,27±0,10*
SOMO %8,49±0,09of 8.47±0,128,65±0,11*
Total protein, %3,06±0,083,30±1±0,07of 3.46±0,06*
Milk sugar, %to 4.52±0,11with 4.64±1±8,804,82±0,06±
Ash, %0,78±0,010,79±0,090,79±0,1
Calcium, mg%96,4±0,17of 98.2±0,36104,6±0,22*
Phosphorus, mg%78,6±0,0882,8±0,21*84,0±0,25*
Potassium, mg%139,0±2,92140,8±2,35141,9±2,72
Density,°And27,90±0,3228,50±0,4028,98±0,25*
Acidity, T°17,70±0,3317,68±0,36 17,28±0,12
pH6,67±0,086,51±0,116,40±0,10
The number of fat globules, bn/mg3,21±0,103,2B±0,153,49±0,05*
The average diameter of the balls, mcm2,88±0,112,98±0,143,20±0,08*
Energy value of 1 kg of milk, kcal614,3627,5645,8
Note: * - P<0,05

The solids content in milk of cows from the experimental group 2 was the most high - 12,27±0,10% (table 2). The lower the solids content was in the milk of cows from the experimental group 1 (12,08±0,08%) and especially in cows of the control group (11,95±0,09%).

SOMO milk of animals of the experimental group 2 is significantly higher (0.16%), protein - 0.40%, relative to milk the control group. The SNF content in milk of cows 1st experimental and control group 1 was the same. Protein content in milk of cows fed sodium Selenite, was 0.24% more than in the control.

Lactose content was significantly higher in the milk of animals treated with selenium products: the appointment of sodium Selenite 0.12% more than in the control milk cows, and in the appointment of selecor - 0.30%).

The highest calcium content was Moloka cows experimental group 2 - 8.2 mg% higher than in the milk of cows of the control group (P<0,05). Phosphorus in milk of animals in experimental groups 1 and 2 was greater than in control 4.2 and 5.6%, and the potassium content of the milk from the cows of the experimental groups only 1-2 mg% exceeded the level in the milk of cows of the control group.

According to research, the number of fat globules in the milk of cows from the experimental group 2 was significantly higher than in cow milk control. The use of sodium Selenite had insignificant impact on their numbers. The average diameter of the fat globules was also greatest in the milk of cows from the experimental group 2, 3,20±0,08 m in diameter 2,88±0.11 and 2,98±0,14 m in milk control and experimental group 1, respectively (P<0,05).

In the milk of cows of the control group density was lower than the density of milk from cows of the experimental group 1 0.60°And, experienced 2 - 1.08°While (P<0,05). When conducting sensory evaluation of milk from cows experimental and control groups, significant difference was not detected. Freshly-milked milk from all animals was identical in appearance, smell, taste and texture and was a homogeneous liquid is white with a slightly yellowish tinge, specific pleasant smell, a pleasant, sweet taste.

Energy value of 1 kg of milk from cows of the experimental group 1 above 13.2 kcal, and from cows experimental group 2 - 31.5 QC is l above, than milk cows in the control group.

The cost of feed per 1 kg of milk in the appointment of selecor reduced by 0.1 feed unit or 8.9%.

Thus, studies have shown that use of the drug Selena selecor monthly intramuscular dose of 10 mg/kg of body weight, helps to increase milk production and improve milk quality.

Example 2.

The effect of the proposed method on homeostasis, productivity, carcass and meat quality of veal calves in the settlements.

Scientific and economic experiment to study the influence of the claimed and known methods for meat production, carcass and meat quality of veal calves was conducted on three groups of animals (control and two experimental), similar to the breed, live weight, sex and age (6-7 months), and 15 animals each. Calves experimental groups intramuscularly, once a month was prescribed selenium products: sodium Selenite at a rate of 0.1 mg/kg body weight in 0.5%aqueous solution (experimental group 1) and selecor at a dose of 10 g/kg body weight (LW) (experimental group 2). The calves of the control group of drugs are not used.

The experimental calves at the beginning and end of the observation took blood samples for morphological and biochemical studies, have identified body mass weighting for evaluation of carcass and meat quality of animals tested on 3 calves from each group were killed who at the factory.

The experimental calves in the beginning of the experiment was reduced appetite, taste perverted, licking objects, fatness below average, hair disheveled, hair brushed. The mucous membranes in calves pale, some animal feces somewhat diluted, liver palpation is painful. Body temperature was within the physiological norm, the number of respiratory movements and heart rate increased.

Table 3.
Hematological parameters of calves treated with sodium Selenite and selecor.
IndicatorsTo experienceGroup
ControlExperienced 1Experienced 2
Erythrocytes, 1012l7,25±0,17,4±0,26,5**±0,2*6,4**±0,2*
Leukocytes, 109l6,9±0,36,3±0,48,6**±0,15*8,2±0,25*
Hemoglobin, g/l81,7±1,2an 80.2±3,194,0±4,1*102,0**±3,4*
Color index0,67±0,10,64±0150,90±0,030,95±0,5
Note: * - P<0.05 to background; ** - P<0.05 to control.

The clinical condition of the calves of the control group during the observation period did not change significantly, and the calves of the experimental groups improved. Significantly improved appetite, normalized fatness, the gastro-intestinal tract, the normal stool consistency, mucous membranes of eyes, mouth turned pale pink color.

In the beginning of the experiment, the number of erythrocytes (7,25±0,10), leukocytes (6,9±0,3) in the blood of the calves were within normal limits and somewhat reduced color indicator (0,67±0,1) (table 3).

After injection of selenium the number of erythrocytes in the blood of the calves of the experimental groups decreased: when assigning selecor (experimental group 2) by 11.7% to the background and 13.5% for the control, and in the appointment of sodium Selenite (experimental group 1) - 10.4% compared to control.

Animals in all experimental groups the color indicator is normalized due to a slight decrease in the number of erythrocytes and increased levels of hemoglobin. The hemoglobin content in calves in experimental groups compared to the control was set significantly higher (P<0,05). The number of leukocytes in the blood of the calves of the experimental group increased by 18.8 to 24.6% (P<0,05).

When analyzing leukogram found that the number of eosinophils in connection with the use of selenium preparations fell 38.5-53.9% of % (P&t; 0,05).

To determine the effect of the claimed and known methods to increase productivity of cattle was carried out biochemical analysis of the blood of the calves. The results are presented in table 4.

Table 4.
Biochemical parameters of blood of calves in the appointment of selenium products.
IndicatorsBackgroundGroup
controlexperienced 1Experienced 2
Total protein, g/l72,3±0,578,3±0,475,2**±1,1*75,1**±0,9*
Albumin, g/l14,2±2,3615,4±and 2.2620,8±1,7*25,0**±2,5*
α-globulin, g/l41,9±3,5241,3±3,4730,6*±1,79*26,9**±2,41*
β-globulins6,0±0,6610.1±3,1510,2±1,09*8,9±1,23*
γ-globulin, g/l10,2±0,2911,0±0,8613,6±1,18*14,3**±1,03*
The factor a/g0,240,25,38 0,50
Phosphorus, mmol/l1,25±0,091,2±0,081,46**±0,041,4**±0,09
Calcium, mmol/l1,70±0,091,69±0,0751,86±0,05*2,03**±0,07*
The ratio of CA: P1,36:11,40:11,27:11,45:1
Alkaline phosphatase, kat/l4,13±0,073,98±0,043,61*±0,09*3,86**±0,03*
AST, mm/l1,87±0,021,78±0,051,65±0,04*1,45**+0,03*
Alat, mm/l0,88±0,030,83±0,040,65±0,02*0,57**±0,03*
The coefficient of Rytis, ASAT/Alat2,122,142,532,54
Glucose, mm/l1,749±0,071,58±0,052,28**±0,07*2,34**±0,025*
Cholesterol, mmol/l3,13±0,183,09±0,162,90±0,262,80**±0,1*
Malonic dialdehyde, mm/l0,34±0,020,37±0,030,30±0,010,29±0,02
When echange:

* - P<0.05 with respect to the background, to experience;

** P<0.05 with respect to control group.

Animals in all groups, the total protein content (table 4) were within normal limits (72,3-to 78.3 g/l). The amount of albumin in the serum of animals in all groups at the beginning of the experiment was low. However, after applying selecor concentration of albumin in the serum of animals increased by 76% and 46% in the appointment of sodium Selenite, and in the control group only by 8.4% to the original level. Level γ-globulin also significantly increased in the serum of calves of the experimental groups to the original level and to control (40,2-30,0%).

The level of AST and Alt in the blood of animals from the experimental group 2 decreased by 22.5 35.3% and 11.8 and 26.1% in calves from the experimental group 1 compared with baseline. Results are consistent with studies Vasodilan etc. /5/, indicating that the increased activity of ASAT and Alat indicates low levels of selenium in the body.

The glucose content in the beginning of the experiment in the blood of the calves was less than the physiologically normal for animals of this age. After injection of selenium content in blood glucose in experimental calves were significantly increased at 44-48,1% (P<0,05).

The cholesterol level in the blood of the calves in the beginning of the experiment was high, which is typical for violations libidn the th metabolism (liver). Normal cholesterol in the blood should be 0,78-1,03 mm/l After supplementation of selenium in animals of experimental groups of cholesterol in the blood decreased and remained unchanged in the blood of the calves of the control group.

To experience the activity of Alp was 4,13±0.07 mmol/l, slightly above normal (0,4-3,83 mm/l). As a result of application of selenium-containing drugs she fell 6.5-13.4 per cent. The content of phosphorus and calcium in the blood of all the experimental calves were low. During the period of experiment the content of calcium in the blood serum of the calves of the control group remained almost unchanged - 1,69±0,075 mm/L. However, in animals of the experimental group 1 calcium levels increased by 9.4 and 19.4% in the blood of the calves from the experimental group 2. The phosphorus content in the blood of the calves in the control group by the end of the experiment decreased to 1.20±0.08 mm/l, and in the blood of the calves of the experimental groups, the concentration of phosphorus increased by 11.2-11.7 per cent (P<0,05). Therefore, the use of drugs selenium improves the morphological composition of the blood, metabolism, resulting in indicators of metabolism (protein, fat, carbohydrate and mineral) are normalized. This is confirmed by the decrease in the body calves secondary products of lipid peroxidation - calves of the experimental groups, the content of malondialdehyde (MDA) decreased by 11.8-14,3, whereas in the blood of the control group it increased by 8.8% compared with the original.

The use of selecor had a positive impact on the growth of calves. Daily gains of body weight in calves from the experimental group 1 was 25.4% higher than in the control, and was 823,3±30,3, the Best results on the gain obtained from animals of the experimental group 2-910,0±25,3 g or by 38.6% higher than in calves of the control group (656,7±20,1 g).

The cost of feed per 1 kg increase in decrease in the appointment of sodium Selenite by 6.4% and 16.5% when using selecor.

Table 5
The results of the control slaughter
IndicatorsGroup
controlexperienced 1experienced 2
Pre-slaughter weight, kg174,2+2,15180,4+3,2182,0+2,04*
Carcass weight, kg84,1 to+0.6588,6+0,90*91,0+2,12*
Weight of internal fat, kg2,7±0,093,05+0,103,30+0,12*
Carcass fat+kg86,8+0,4591,65+0,45*94,3+1,90*
The output of the carcass, %48,3±0,1649,1+0,13*50,+0,25*
Slaughter yield, %49,8+0,3251,7+0,3651,8+0,40*

The maximum increase in live weight obtained in calves receiving selecor by the present method. They had the lowest content in serum MDA, which explains to some extent the effects of selenium on the growth of animals. Maximum pre-slaughter weight had animals of the experimental group 2. She was 182,0+2,04 kg and exceeded the body weight of calves from experimental group 1 by 1.6 kg, and slaughter calves of the control group - 7.8 kg or 4.5%. Slaughter weight (carcass fat+) respectively was higher in calves from the experimental group 2 7.5 kg and 4,85 kg in calves from the experimental group 1. Significantly higher in calves from the experimental group 2 was a killer, he was 51.8+0,40%, which exceeded the slaughter yield in calves from the experimental group 1 at 1.9%, and calves of the control group by 2.0% (table 5).

Table 6.
Morphological composition of carcasses.
IndicatorsGroup
controlexperienced 1experienced 2
Carcass weight, kg82,6+0,7586,8±1,20*90,6±1,95*
The mass of pulp, kg58,6±8,1063,19±1,95 66,5±1,31*
The output of pulp, %70,972,873,4
The bone mass, kg20,8±1,4421,7±1,3822,1±1,40
The output of the bones, %28,725,024,4
The output of the cartilage and tendons in kg2,9±0,121,7±0,132,0±0,11
In %3,52,01,8
Index macnasty2,822,913,00
Loss, %0,40,20,4

The data of the morphological composition of the carcasses (table 6) from the experimental calves indicate that mass of flesh in carcasses from animals of the experimental group 2 was greater than in the control carcasses of calves 13.5% (P<005) and 5.7% more than in the carcasses of calves treated with sodium Selenite (experimental group 2). With the increase in the body content of the pulp (carcasses) reduced the proportion of bones (13-15% less than in control, in the carcasses of calves experimental groups). The ratio of flesh and bones (index macnasty) was higher, respectively, in the carcasses of calves experimental groups (2,91-3,0, when 2,82 carcasses of calves in the control group).

Therefore, using the proposed method provides a higher growth rate of calves and the more high carcass and meat quality

Table 7
Chemical composition and caloric value of meat in experimental calves.
IndicatorsGroup
controlexperienced 1experienced 2
Moisture, %74,66+0,6871,99±0,83*70,76+0,67*
Dry matter, %25,34+0,4028,01+0,3229,24+0,28
Fat, %or 10.60+0,2611,12+0,28*11,99+0,22*
Protein,%14,27+0,4415,93+0,47*16,29+0,27*
Ash,%0,97+0,010,96+0,020,97+0,01
The caloric content of 1 kg of meat, kcal154716631755
The ratio of fat and moisture - maturity" meat7,39of 6.495,91
The ratio of Protein: fat1,41:11,43:11,36:1
Note: * - P<0,05

The water content in the meat of calves fed sodium Selenite and selecor was significantly less (P<0,05) 1,94 was 2.76%, more fat 0.91-1.01% and more protein by 1.01-1.66 per cent, than in the meat of calves of the control group is s (table 7). In the meat of calves from experimental group 2 this pattern is more pronounced.

Calorie meat calves from the experimental group 2 was higher than the caloric value of meat animals in the control group 208 kcal (13.5%), whereas the calorie meat calves from the experimental group 1 was higher than the control only 116 calories or 7.5%.

Consequently, the application of the proposed method increases the chemical composition and caloric value of meat.

When tasting meat and broth from meat is the most delicious, juicy and flavorful meat was from calves from the experimental group 2, estimated at 8,55 points, 0.27-0.33 points higher than the rating of the meat from calves of the control and experimental group 1.

Fried meat and broth, obtained by cooking meat from animals of the experimental group 2, were evaluated higher than calves of the control and experimental group 1.

Data on productivity, quality meat indicate that the use of selecor not only increases productivity, but also improves the quality of the meat.

Thus, the research results indicate the positive effect of using the proposed method on milk production and milk quality: application of selecor provides increased yields by 8.0%, while the introduction of sodium Selenite milk yield increased only 3.0%. In milk of cows with higher dry matter content by 12.27%, SOMO 0.16%, protein 0.40%, lactose n is between 0.30%, calcium 8.2 mg%, phosphorus 5.6 mg%, increased the number and size of fat globules with lower acidity. As a consequence, the energy value of milk above 31.5 kcal than milk from cows of the control group. The cost of feed to produce 1 kg of milk with basic fat content of 3.8% in cows when assigning selecor less than 7.7%, and in the application of Selenite - 5.0%.

Application of the proposed method cows, young cattle economically as a result of improved productivity and lower costs for feed to the synthesis of the products obtained.

Sources of information

1. Trifonov GA study of the introduction of selenium-containing drugs on cows with subclinical cytosol// Materials of international scientific-practical conference "Actual problems of veterinary medicine", dedicated to the 60th anniversary of the faculty of veterinary medicine of Ulyanovsk state agricultural Academy, 25-26 September 2003 GT. - Ulyanovsk, 2003. -S-146.

2. EN 2002112880 AND published 2003.12.10, CL 7 IPC D 7/00 A 61 And 61 To 33/04.

3. EN 2002112883 AND published 2003.12.27, CL 7 IPC D 7/00 A 61 And 61 To 33/04. (Prototype).

4. Sanotski IV Indispensable selenium// Essential selenium. Prevention and treatment of diseases. - M., 2001. - P.3-12.

5. Tutelian IV, Knyazev VA, Khotimchenko S.A., Golubkina N.A., Kuklinski N.E. Sokolov AA Selenium in the human body: metabolism, antioxidant t the VA, role in carcinogenesis. - M.: publishing house of the Russian Academy of medical Sciences, 2002. - 224 S.

The way to increase cattle productivity, including the use of selectabase organic drug, characterized in that the drug is used selecor applied cows and calves monthly intramuscularly at a dose of 10 mg/kg of body weight.



 

Same patents:

FIELD: organophosphorus compounds, medicine.

SUBSTANCE: invention relates to new biologically active phosphonate compounds. Invention describes phosphonate compound of the formula:

wherein R1 and R'1 represent independently hydrogen atom (-H) substituted possibly with -O-(C1-C24)-alkyl, -O-(C1-C24)-alkenyl, -O-(C1-C24)-acyl, -S-(C1-C24)-alkyl, -S-(C1-C24)-alkenyl or -S-(C1-C24)-acyl wherein at least one among R and R'1 doesn't represent -H and wherein indicated alkenyl or acyl comprise from 1 to 6 double bonds; R2 and R'2 represent independently -H substituted possibly with -O-(C1-C7)-alkyl, -O-(C1-C7)-alkenyl, -S-(C1-C7)-alkyl, -S-(C1-C7)-alkenyl, -O-(C1-C7)-acyl, -S-(C1-C7)-acyl, -N-(C1-C7)-acyl, -NH-(C1-C7)-alkyl, -N-((C1-C7)alkyl)2, oxo-group, halogen atom, -NH2, -OH or -SH; R3 represents phosphonate derivative of nucleoside or biphosphonate; X represents compound of the formula:

L represents a valence bond or a bifunctional binding molecule of the formula: -J-(CR2)t-G- wherein t is a whole number from 1 to 24; J and G represent independently -O-, -S-, -C(O)O- or -NH-; R represents -H, unsubstituted or substituted alkyl or alkenyl; m means a whole number from 0 to 6; n = 0 or 1. Also, invention describes pharmaceutical compositions comprising phosphonate compounds, method for treatment of osteoporosis in mammal, method for increasing mineral osseous density, method for prophylaxis of apoptosis of osteoblasts and osteocytes in mammal, method for treatment of viral infection in mammal, method for treatment of growing neoplasm in mammal and method for proliferation of cells. Invention provides preparing new compounds eliciting useful biological properties.

EFFECT: valuable medicinal properties of phosphonate compounds.

17 cl, 2 dwg, 7 tbl, 21 ex

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to methods for treatment of diseases or syndromes associated with metabolism of fatty acids and glucose and to new compounds and their pharmaceutically acceptable salts. Invention relates to applying new compounds and pharmaceutical compositions for treatment of cardiovascular diseases, diabetes mellitus, cancer diseases, acidosis and obesity by inhibition of activity of enzyme malonyl-CoA-decarboxylase. Indicated compounds correspond to formulae (I) and (II) wherein Y, C, R1, R2, R6 and R7 have values given in the invention claim.

EFFECT: valuable medicinal and biochemical properties of azoles.

27 cl, 8 tbl

FIELD: endocrinology.

SUBSTANCE: abnormally corpulent persons are treated by reduced-caloricity diet with limited content of carbohydrate-containing components and fats. In particular, caloricity of meal is reduced to 1200 kcal, including carbohydrate-containing components with glycemic index below 40. When initial weight is reduced by 5% and the weight is stabilized for 3 months, caloricity is increased to a specified value, calculated in terms of formula for daily caloricity recommended by World Health Organization taking into account sex, age, weight, and physical activity, glycemic index of carbohydrate-containing components ranging from 40 to 69 until the weight is lowered to desired level.

EFFECT: achieved stable and long-term reduction of weight owing to lowered insulin resistance of organism.

3 tbl

FIELD: animal science.

SUBSTANCE: calves should be fed with a complex of biologically active substances obtained out of Chlorella Vulgaris suspension since the 2nd d of their life, once daily before morning feeding at the quantity of 100 ml/calf, and beginning since the 11th d - 200 ml/calf according to the same scheme. Total duration of the whole course corresponds to 21 d.

EFFECT: increased inspecific body resistance in cattle youngsters.

1 tbl

FIELD: veterinary science.

SUBSTANCE: one should apply liniment that contains an active substance being "Todicamp-ideal" and a vegetable foundation as a mustard-pumpkin fuse obtained while manufacturing "Volgogradskoe" vegetable oil at weight ratio of mustard and pumpkin oils being 1:9 weight portions. Moreover, "Todicamp-ideal" and mustard-pumpkin fuse are at weight ratio of 10-12 : 90-88 weight portions. In some cases of liniment application upon affected part of cow's udder should be combined with peroral intake of "Todicamp-ideal". The innovation provides simultaneous antiphlogistic, antimicrobial and immunostimulating effect.

EFFECT: higher efficiency of therapy.

2 cl, 2 ex, 1 tbl

FIELD: agriculture, veterinary science.

SUBSTANCE: during the 1st d after forming raising groups one should once inject intramuscularly a solution of "Complex A" preparation at the dosage of 0.30-0.32 mg/kg body weight for 45-60-d-aged piglets and simultaneously with fodder one should introduce "Lactobifadol" preparation at the quantity of 0.50-0.52 g/kg body weight during the first 1-5 d. The present innovation enables to activate immune system, increase total protein and hemoglobin in blood that in its turn, prevents bronchopneumonia and remove stress in piglets after forming special raising groups.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with medicinal preparations for increasing total and specific stimulation of animal body. The suggested preparation should be obtained out of drone bee larvae of different age. From the cells of drone bee brood one should cut off convex wax caps with a special knife for opening honeycombs, then due to light knocking one should remove larvae out of the cells into a cuvette to be put into vials. Larvae should be frozen and homogenized, moreover, as a stabilizing medium one should apply 5%-glucose solution at 1:10 ratio at addition of 5%-chloroform solution or 2%-salicylic acid followed by sublimation to be finally poured into vials per 5 ml. Moreover, sublimation should be fulfilled in vacuum chamber at temperature of shelves' heating up to 30-45 C. At achieving preparation temperature of 20-22 C shelves' temperature should be decreased up to 25 C to perform final heating for 22-24 h. The method provides increased total and specific stimulation of animal body due to applying cheaper and more available biostimulant.

EFFECT: more simplified method of manufacturing.

3 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: as an immunomodulating remedy one should introduce tamerite per 0.5 ml subconjunctivally and per 1.5 ml i/m daily for 5 d. The method provides normalization of immunity values due to additional local complex manifestation of immunomodulating, antiphlogistic, antioxidant and regenerating effects of tamerite.

EFFECT: higher efficiency of complex therapy.

2 ex

FIELD: medicine, oncourology.

SUBSTANCE: the present innovation deals with conservative treatment of patients with malignant prostatic tumor at different stages. The method includes testicular enucleation, introduction of anti-tumor chemopreparations and radiation therapy. Moreover, in the onset of radiation therapy one should introduce 25 mg Cisplatin incubated with 10 ml patient's plasma into both prostatic lobes and paraprostatic fiber from the right and from the left. At achieving a focal dosage of 20 Gy one should repeat introduction of chemopreparation in similar dosage, and radiation therapy should be continued up to total focal dosage of 40 Gy. The innovation enables to decrease tumor sizes, side manifestations of radiation therapy at decreasing radiation loading and improve patient's life quality due to mitigating the urination.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, surgery.

SUBSTANCE: method involves carrying out an antibacterial therapy and additional administration of curative mixture consisting of one part of dimexide, two parts of 0.5% of novocaine solution with antibiotic eliciting high the bacteriostatic activity against microflora in duct secret. Administration of this curative mixture is carried out by catheter into injured duct directly by course 1-2 times. Invention promotes to topical sanitation of mammary gland duct and reducing time of disease. Invention can be used in treatment of galactophoritis.

EFFECT: improved method for treatment.

1 ex

FIELD: medicine, dermatology, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to an antifungal gel pharmaceutical composition based on ketoconazole and clotrimazole that are derivatives of imidazole. The composition comprises ketoconazole or clotrimazole as an active component, polyethylene glycol-400 (PEG-400) as a solvent, carboxyvinyl polymer as a gel-forming agent, polyethylene glycol as a gel stabilizing agent, organic amine or inorganic bas as a regulator of pH and water taken in the definite ratio of components. The composition is prepared by dissolving active component in PEG-400, dispersing carboxyvinyl polymer in water, successive addition to dispersion propylene glycol as a stabilizing agent and regulator of pH and combination of prepared solution and gel followed by stirring the mixture up to preparing the gel composition with pH 5-7. Invention provides preparing antifungal composition with reduced adverse effect.

EFFECT: improved preparing method, valuable medicinal properties of composition.

2 cl, 1 tbl, 11 ex

FIELD: medicine, gynecology, anesthesiology.

SUBSTANCE: invention concerns to a method for carrying out the anesthesiology assistance for woman in childbirth with accompanying bronchial asthma. Method involves administration of atropine, dimedrol, analgin and clophelin. Method involves additional intravenous administration of transamine for 5-7 min. Transamine is administrated in doses 12-14 and 15-17 mg/kg in woman in childbirth with body mass 75 kg and above and 74 kg and less, respectively. Method provides enhancing quality and safety of anesthesia in this class of woman in childbirth.

EFFECT: improved assistance method.

7 tbl, 4 ex

FIELD: veterinary science.

SUBSTANCE: a dog should be introduced with 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazole-1-il]benzene sulfonamide or its pharmaceutically acceptable salt at daily dosage ranged about 0.1-10 mg/kg body weight.

EFFECT: higher efficiency of therapy.

4 cl,262 ex, 12 tbl

FIELD: organic chemistry and pharmaceutical compositions.

SUBSTANCE: invention relates to new 3-(5)-heteroaryl-substituted pyrazoles of formula I , tautomers or pharmaceutically acceptable salt of compounds and tautomers. In formula R1 is hydride, piperidinyl substituted with methyl, lower alkyl optionally substituted with halogen, hydroxyl, lower alkylanimo or morpholino; R2 is hydride, lower alkyl, amino, aminocarbonylamino, lower alkylaminocarbonylamino, lower alkylsulfonylamino, aminosulfonylamino, lower alkylaminosulfonylamino; Ar1 is phenyl optionally substituted with one or more independently selected halogen; HetAr2 is pyridinyl with the proviso that R2 is not amino or n-propyl when HetAr2 is pyridinyl; and HetAr2 is not 2-pyriridinyl when R2 is hydrogen or lower alkyl. Compounds of formula I have kinase p38 inhibitor activity and are useful in pharmaceutical compositions for treatment of various diseases.

EFFECT: new effective kinase p38 inhibitors.

23 cl, 6 dwg, 1 tbl, 1 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new 1-(p-thienylbenzyl)-imidazoles of the formula (I): , wherein indicated residues represent the following values: R(1) means halogen atom, (C1-C4)-alkoxyl, (C1-C8)-alkoxyl wherein one carbon atom can be replaced with heteroatom oxygen atom (O); R(2) means CHO; R(3) means aryl; R(4) means hydrogen halogen atom; X means oxygen atom; Y means oxygen atom or -NH-; R(5) means (C1-C6)-alkyl; R(6) means (C1-C5)-alkyl in their any stereoisomeric forms and their mixtures taken in any ratios, and their physiologically acceptable salts. Compounds are strong agonists of angiotensin-(1-7) receptors and therefore they can be used as a drug for treatment and prophylaxis of arterial hypertension, heart hypertrophy, cardiac insufficiency, coronary diseases such as stenocardia, heart infarction, vascular restenosis after angioplasty, cardiomyopathy, endothelial dysfunction or endothelial injures, for example, as result of atherosclerosis processes, or in diabetes mellitus, and arterial and venous thrombosis also. Invention describes a pharmaceutical composition based on above said compounds and a method for their applying also.

EFFECT: valuable medicinal properties of compounds and composition.

10 cl, 19 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to a group of new derivatives of 4,5-dihydro-1H-pyrazole of the general formula (I):

wherein R means phenyl, thienyl or pyridyl and these indicated groups can be substituted with (C1-C3)-alkoxy-group or halogen atom; R1 means phenyl that can be substituted with (C1-C3)-alkoxy-group or pyridyl group; R2 means hydrogen atom or hydroxy-group; Aa means one group among the following groups: (i) , (ii) , (iii) , (iv) or (v) ; R4 and R5 mean independently from one another hydrogen atom or (C1-C8)-branched or unbranched alkyl; or R4 means acetamido- or dimethylamino-group or 2,2,2-trifluoroethyl, or phenyl, or pyridyl under condition that R5 means hydrogen atom; R6 means hydrogen atom at (C1-C3)-unbranched alkyl; Bb means sulfonyl or carbonyl; R3 means benzyl, phenyl or pyridyl that can be substituted with 1, 2 or 3 substitutes Y that can be similar or different and taken among the group including (C1-C3)-alkyl or (C1-C3)-alkoxy-group, halogen atom, trifluoromethyl; or R3 means naphthyl, and its racemates, mixtures of diastereomers and individual stereoisomers and as well as E-isomers, Z-isomers and mixture of E/Z-compounds of the formula (I) wherein A has values (i) or (ii), and its salt. These compounds are power antagonists of Cannbis-1 (CB1) receptor and can be used for treatment of psychiatric and neurological diseases. Except for, invention relates to a pharmaceutical composition used for treatment of some diseases mediated by CB1-receptor, to a method for preparing this composition, a method for preparing representatives of compounds of the formula (I) wherein Aa means group of the formulae (i) or (ii), intermediate compounds used for preparing compounds of the formula (I) and to a method for treatment of some diseases mediated by CB1-receptor.

EFFECT: valuable medicinal properties of compounds.

16 cl, 9 ex

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with treating patients with uterine cervix cancer with relapses in parametral fiber and in case of no possibility for radical operative interference and effect of previous radiation therapy. During the 1st d of therapy one should intravenously inject 30 mg platidiam incubated for 1 h at 37 C with 150 ml autoblood, during the next 3 d comes external irradiation per 2.6 G-r. During the 5th d of therapy one should introduce the following composition into presacral space: 60 ml 0.5%-novocaine solution, 1 ml hydrocortisone suspension, 2 ml 50%-analgin solution, 1 ml 0.01%-vitamin B12 solution, 1.6 g gentamycine, 800 mg cyclophosphan, 10 mg metothrexate. These curative impacts should be repeated at mentioned sequence four times. The method enables to decrease radiation loading and toxic manifestations of anti-tumor therapy at achieving increased percent of tumor regression.

EFFECT: higher efficiency of therapy.

1 ex

The invention relates to new compounds of the formula (I)

in which Ar1means pyrazole which may be substituted by one or more groups R1, R2or R3; Ar2means naphthyl, tetrahydronaphthyl, each of which is optionally substituted by 0-1 groups R2; X means5-C8cycloalkenyl, phenyl, optionally substituted by a hydroxy-group or1-C4alkoxygroup, furan, pyridinoyl, pyrazolyl, pyridinyl, optionally substituted by a hydroxy-group or1-C4alkoxygroup, piperidinyl; Y represents a bond or a saturated branched or unbranched1-C4the carbon chain, with one methylene group is optionally replaced with NH, or and Y is optionally independently substituted by oxopropoxy; Z means morpholine, group, pyridinyl, furanyl, tetrahydrofuranyl, thiomorpholine, pentamethylbenzene, pentamethylbenzene, secondary or tertiary amine, the nitrogen atom of the amino group covalently linked to the following groups selected from a range that includes the C1-C3alkyl and C1-C5alkoxyalkyl; R1means31-C6alkyl which is optionally partially or fully galogenidov, halogen; R3means phenyl, pyrimidinyl, pyrazolyl, which is substituted by one branched or unbranched1-C6the alkyl, and pyridinyl, optionally substituted C1-C3alkoxygroup or amino group, W denotes O and its pharmaceutically acceptable salts

The invention relates to chemical-pharmaceutical industry, in particular to the creation and production of tools for the treatment of skin diseases

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with treating patients with uterine cervix cancer with relapses in parametral fiber and in case of no possibility for radical operative interference and effect of previous radiation therapy. During the 1st d of therapy one should intravenously inject 30 mg platidiam incubated for 1 h at 37 C with 150 ml autoblood, during the next 3 d comes external irradiation per 2.6 G-r. During the 5th d of therapy one should introduce the following composition into presacral space: 60 ml 0.5%-novocaine solution, 1 ml hydrocortisone suspension, 2 ml 50%-analgin solution, 1 ml 0.01%-vitamin B12 solution, 1.6 g gentamycine, 800 mg cyclophosphan, 10 mg metothrexate. These curative impacts should be repeated at mentioned sequence four times. The method enables to decrease radiation loading and toxic manifestations of anti-tumor therapy at achieving increased percent of tumor regression.

EFFECT: higher efficiency of therapy.

1 ex

Up!